[Proton therapy in soft tissue and bone sarcomas].
Abstract Sarcomas are a common type of tumor within the pediatric population. The utilization of proton therapy as a primary attribute the ability to spare adjacent healthy tissue, therefore, proton therapy has become a preferential indication in pediatrics compared to other photon irradiation modalities. Proton therapy is also a proven and historically validated irradiation technique in the treatment of chondrosarcomas and chordomas of the skull base and spine. Additionally, proton therapy can potentially limit irradiated healthy tissue volumes in adults and limit the risk of acute and late toxicities. The evalua...
Source: Bulletin du Cancer - August 17, 2018 Category: Cancer & Oncology Authors: Thariat J, Tessonnier T, Bonvalot S, Lerouge D, Mammar H, Bolle S, Claren A, Duffaud F, Alapetite C, Vogin G Tags: Bull Cancer Source Type: research

[The CAR-T cells are here].
Abstract Due to immunotherapy, a new era of treatment is opening up for the treatment of solid cancers and hematological tumors. T cells genetically modified with a chimeric antigen receptor (CAR-T cells) have recently been proved efficient in hematological malignancies expressing CD19. On June 20th 2018, the European Medicines Agency gave a favorable opinion on two types of anti-CD19 CAR-T cells - tisagenlecleucel and axicabtagène ciloleucel - in the management of malignant hemopathies B after two lines of treatment. Their remarkable efficacy has been demonstrated in the first clinical ...
Source: Bulletin du Cancer - August 14, 2018 Category: Cancer & Oncology Authors: Croizier C, Douge A, Bay JO, Lemal R Tags: Bull Cancer Source Type: research

[Reprint of: Treatment of patients with inoperable stage III or stage IV melanoma. Soci été française de dermatologie].
[Reprint of: Treatment of patients with inoperable stage III or stage IV melanoma. Société française de dermatologie]. Bull Cancer. 2018 Aug 13;: Authors: Guillot B, Charles J, Jeudy G, Cupissol D, Dupuy A, Dutriaux C, Gangloff D, Magne N, Mirabel X, M'Sadek A, Pracht M, Sichel C, Do Outeiro G PMID: 30115366 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - August 13, 2018 Category: Cancer & Oncology Authors: Guillot B, Charles J, Jeudy G, Cupissol D, Dupuy A, Dutriaux C, Gangloff D, Magne N, Mirabel X, M'Sadek A, Pracht M, Sichel C, Do Outeiro G Tags: Bull Cancer Source Type: research

[5-fluorouracil therapeutic drug monitoring: Update and recommendations of the STP-PT group of the SFPT and the GPCO-Unicancer].
Abstract Despite being 60-years old now, 5-FU remains the backbone of numerous regimen to treat a variety of solid tumors such as breast, head-and-neck and digestive cancers either in neo-adjuvant, adjuvant or metastatic settings. Standard 5-FU usually claims 15-40% of severe toxicities and up to 1% of toxic-death. Numerous studies show a stiff relationship between 5-FU exposure and toxicity or efficacy. In addition, 5-FU pharmacokinetics is highly variable between patients. Indeed, 80% of the 5-FU dose is catabolized in the liver by dihydropyrimidine dehydrogenase (DPD) into inactive compounds. It is now well est...
Source: Bulletin du Cancer - August 10, 2018 Category: Cancer & Oncology Authors: Lemaitre F, Goirand F, Launay M, Chatelut E, Boyer JC, Evrard A, Paludetto MN, Guilhaumou R, Ciccolini J, Schmitt A Tags: Bull Cancer Source Type: research

[Medical treatment of small cell lung cancer: Can we leave the area of cisplatin-etoposide?]
Abstract Small cell lung cancer accounts for 14% of all lung cancers. It remains a major challenge for oncology as the progresses made in the past three decades are modest. After a rapid overview of current knowledge regarding somatic genomic alterations, this state-of-art addresses pathways to improve small-cell lung cancer outcome such as the targeting of DNA damage repair mechanisms firstly anti-PARPs, inhibitory molecules of EZH2, derepression of the NOTCH pathway, rovalbituzumab-tesirine, inhibition of serine/threonine Aurora A kinase, temozolomide and its dependence on methylation of the MGMT promoter. This ...
Source: Bulletin du Cancer - August 9, 2018 Category: Cancer & Oncology Authors: Pujol JL, Roch B, Pujol CN, Goze C Tags: Bull Cancer Source Type: research

[Supportive care for survivors].
This article aims to review the facilitators and obstacles of this perspective. PMID: 30097280 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - August 7, 2018 Category: Cancer & Oncology Authors: Ninot G, Debourdeau P, Blanc-Legier F, De Crozals F, De Rauglaudre G, Khouri S, Kirscher S, Mineur L, Piollet I, Sant I, Schillinger P, Serin D Tags: Bull Cancer Source Type: research

[Integrated podiatrist care for prostate cancer patients treated with docetaxel: Feasibility and results].
CONCLUSION: The integration of podiatrist care is feasible in routine cancer care and can help improving the management of docetaxel-induced nail toxicity in metastatic prostate cancer patients. PMID: 30078546 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - August 2, 2018 Category: Cancer & Oncology Authors: Chabanol H, Huillard O, Prin L, Villeminey C, Rondeau A, Boudou-Rouquette P, Astorg F, Musenghesi B, Du Mortier C, Alexandre J, Goldwasser F Tags: Bull Cancer Source Type: research

Small cell carcinoma of the endometrium: A clinicopathological study and management of three cases.
Abstract Endometrial small cell carcinoma (ESCC) is an extremely rare and aggressive tumor with poor prognosis. It is characterized by early regional and systemic spread leading to rapid development of lymph nodes, pelvic and extrapelvic metastasis and compromising the outcome. In this paper, we reported three cases of ESCC confirmed by pathological and immunohistochemistry studies. In one case, ESCC was associated with endometrioid carcinoma and carcinosarcoma, while the other two cases were pure ESCC. Two cases were diagnosed at early stage IA of the International Federation of Gynecology and Obstetrics (FIGO) c...
Source: Bulletin du Cancer - July 26, 2018 Category: Cancer & Oncology Authors: Sidibe FM, Traore Z, Georgala A, Kanab R, Larsimont D, Awada A, Piccart-Gebhart M Tags: Bull Cancer Source Type: research

[Impacts of routine patient-reported-outcomes monitoring in oncology].
dé N PMID: 30032955 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - July 19, 2018 Category: Cancer & Oncology Authors: Fiteni F, Favier M, Bascoul-Mollevi C, Gourgou S, Cousin C, Houédé N Tags: Bull Cancer Source Type: research

[MBD4 inactivation induces a new mutator phenotype in cancers].
PMID: 30032956 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - July 19, 2018 Category: Cancer & Oncology Authors: Rodrigues M, Mobuchon L, Houy A, Derrien AC, Stern MH Tags: Bull Cancer Source Type: research

[Maintenance strategies for advanced pancreatic cancer: Rationale and issues].
PMID: 30029762 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - July 17, 2018 Category: Cancer & Oncology Authors: Turpin A, Chevalier H, Neuzillet C Tags: Bull Cancer Source Type: research

[An analysis of breast cancer treatment waiting times: Experience of a tertiary referral center in Morocco].
Abstract Measuring waiting times is a good indicator of quality and performance of cancer care. However, no detailed evaluation of these deadlines has been carried out in Morocco. The aim of this study was to determine the waiting times of medical care of breast cancer in a national tertiary referral center. The study was carried out by retrospective analysis of 373 cases of patients randomly selected among the cases recruited during the year 2015. Twelve delays of the care pathway were evaluated. The mean age was of 50,7 years. The deadline of access to this center was 9±8days. The deadline of access to th...
Source: Bulletin du Cancer - July 10, 2018 Category: Cancer & Oncology Authors: Mimouni M, Chaouki W, Errihani H, Benjaafar N Tags: Bull Cancer Source Type: research

[Fluoropyrimidines cardiac toxicity: 5-fluorouracil, capecitabine, compound S-1 and trifluridine/tipiracil].
ada D Abstract The incidence of cardiac toxicity of 5-flurorouracil (5-FU) IV and capecitabine varies from 1.2 to 18%. The physiopathology of this toxicity is still under study, various hypotheses are mentioned. In the absence of identified prophylactic treatment, reintroduction of this cytotoxic is at risk. A discussion between oncologists and cardiologists is essential to estimate the balance between benefit and risk and the careful reintroduction of treatment. An alternative compound might be raltitrexed which is currently the treatment recommended in case of intolerance to fluoropyrimidines. The compound S-1 d...
Source: Bulletin du Cancer - June 27, 2018 Category: Cancer & Oncology Authors: Vaflard P, Ederhy S, Torregrosa C, André T, Cohen R, Lopez-Trabada D Tags: Bull Cancer Source Type: research

[What role for the direct oral anticoagulants in oncology?]
PMID: 29960639 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - June 27, 2018 Category: Cancer & Oncology Authors: Lebellec L, Kouakam C, Bertrand N, Penel N Tags: Bull Cancer Source Type: research

[Comparative costs study between ready-to-administer bag of gemcitabine and production in reconstitution unit].
DISCUSSION: Ready-to-administer bags of gemcitabine allow relevant coverage of manufacturing doses. The annual extra cost would reach 37,200€ for our establishment. But, it can be justified by expected benefits: safer medication circuit, saving time of pharmacy technician…. PMID: 29958654 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - June 26, 2018 Category: Cancer & Oncology Authors: Pouplin M, Lortal B Tags: Bull Cancer Source Type: research

[Genomic characterization of head and neck squamous cell carcinoma: Impact and challenges for therapeutic management].
Abstract Squamous cell carcinomas are the most frequent subgroup among head and neck malignant tumors (HNSCC). Tobacco (±alcohol) and HPV infection, the two main risk factors, define two entities with distinct anatomo-clinical and genetic features. HPV-positive, non-tobacco-related HNSCCs are associated with a better prognosis, a rather simple genomic profile, frequent activating mutations of genes involved in pi3kinase-pathway, and the scarcity of mutations of tumor suppressor genes. HPV-negative, tobacco-related HNSCC are genetically more complex, are characterized by almost mandatory inactivating mutatio...
Source: Bulletin du Cancer - June 21, 2018 Category: Cancer & Oncology Authors: Saada-Bouzid E, Milano G, Thariat J Tags: Bull Cancer Source Type: research

R éponse à Braillon et Taiebi.
Réponse à Braillon et Taiebi. Bull Cancer. 2018 Jun 21;: Authors: de Nonneville A, Gonçalves A PMID: 29937335 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - June 21, 2018 Category: Cancer & Oncology Authors: de Nonneville A, Gonçalves A Tags: Bull Cancer Source Type: research

[Early postsurgical temozolomide treatment in newly diagnosed bad prognosis glioblastoma patients: Feasibility study].
CONCLUSION: Early postsurgical temozolomide treatment prior to standard adjuvant therapy for poor prognosis glioblastoma patients in our small prospective series presents toxicity and survival similar to those published in the literature for the general population of glioblastoma. These encouraging results should be confirmed by a multicentric study comparing this regiment with the standard treatment. PMID: 29937336 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - June 21, 2018 Category: Cancer & Oncology Authors: Chaskis E, Luce S, Goldman S, Sadeghi N, Melot C, De Witte O, Devriendt D, Lefranc F Tags: Bull Cancer Source Type: research

[Prescription in oncology: Homeopathy or psychotherapies and nicotine substitutes?]
PMID: 29935913 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - June 20, 2018 Category: Cancer & Oncology Authors: Braillon A, Taiebi F Tags: Bull Cancer Source Type: research

[Definitions of oligometastatic disease and new treatment concepts].
Abstract The definition of oligometastatic disease has evolved into distinct intermediate stages of different prognosis between single metastasis and polymetastatic disease. We assessed the therapeutic impact of such clinical definitions based on a review of the literature. Increasingly advanced stages of the metastatic disease with some prominent oligometastatic targets can be treated with stereotactic irradiation with ablative intent owing to its excellent tolerance profile. Used in different settings, metastatic ablation can either prolong progression free survival, delay change of systemic therapy or delay the...
Source: Bulletin du Cancer - June 20, 2018 Category: Cancer & Oncology Authors: Kissel M, Helou J, Thariat J Tags: Bull Cancer Source Type: research

[Immune checkpoints inhibitors: Recent data from ASCO's meeting 2017 and perspectives].
Abstract Immune checkpoint inhibitors anti-PD-1, anti-PD-L1 and anti-CTLA-4 have been in development in several indications and have changed the face of cancer patients' management. Cancer immunotherapy was central in ASCO's meeting 2017. The identification of patients who could benefit most from immune checkpoint inhibitors is essential. The predictive value of PD-L1 status remains insufficient to select patients who could respond to immunotherapy. An extended search for new biomarkers predictive of response (INF-γ, mutational load) is ongoing, in order to better select responders. Immune checkpoint inhibit...
Source: Bulletin du Cancer - June 19, 2018 Category: Cancer & Oncology Authors: Kfoury M, Disdero V, Vicier C, Le Saux O, Gougis P, Sajous C, Vignot S Tags: Bull Cancer Source Type: research

Exosomes of glioma cells deliver miR-148a to promote proliferation and metastasis of glioblastoma via targeting CADM1miR-148a effect on glioma cells by CADM1.
In conclusion, our findings indicated that miR-148a delivered by exosomes may promote cancer cell proliferation and metastasis via targeting CADM1 to activate STAT3 pathway, suggesting a predictor and therapeutic target role of exosomal miR-148a in GBM patients. PMID: 29921422 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - June 16, 2018 Category: Cancer & Oncology Authors: Cai Q, Zhu A, Gong L Tags: Bull Cancer Source Type: research

[A long-term response to eribulin].
erry JP, Boudin L PMID: 29910045 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - June 14, 2018 Category: Cancer & Oncology Authors: Patient M, Tsogou PTN, Roméo E, Bladé JS, de Jauréguiberry JP, Boudin L Tags: Bull Cancer Source Type: research

[Proton therapy in advanced lung cancer, a clinical phase III trial].
PMID: 29887286 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - June 7, 2018 Category: Cancer & Oncology Authors: Kao W, Thariat J Tags: Bull Cancer Source Type: research

[Participation to organized screening programs: Individual and collective stakes].
This article traces the evolution of the discourse surrounding cancer screening, particularly following the controversy surrounding breast cancer screening. Within the framework of a health policy, screening leads in the first place to a collective benefit and second, to an individual benefit. It describes how, within the French context, the debate has induced a complete re-examination of the modalities of information and consent leading to a shift from the promotion of screening to more balanced information on benefits and risks, so that people can decide whether to participate in a more informed way. PMID: 29853200 ...
Source: Bulletin du Cancer - May 28, 2018 Category: Cancer & Oncology Authors: Launoy G, Duchange N, Darquy S, Moutel G Tags: Bull Cancer Source Type: research

[Leadership influence on safety in cancer care].
res I Abstract Safety in health care is permanently influenced by national and local policies. Since twenty years, number of methodologies and tools inspired from industry, have been implemented to reduce adverse events. Those tools managed to reduce adverse event impact but errors still occur on hospitals and they are difficult to contain. Given the low evolution of the results regarding patient care safety, it seemed important to question other dimensions such as leadership in safety even if the meaning of the word "leadership" is still unknown in almost all hospital organizations. This research analys...
Source: Bulletin du Cancer - May 28, 2018 Category: Cancer & Oncology Authors: Verger D, Boissières I Tags: Bull Cancer Source Type: research

Urging medical students to publish: Advantages, disadvantages and new challenges.
tan J Abstract As soon as they get accepted into medical school, students find themselves facing numerous expectations: coping with tremendous study burden, competing with others for the best rank, completing internships and participating in the race for publishing are only to name a few. This big juggle makes it hard for the medical student to focus on research. It is often easier to postpone publication and involvement in research to "later". In fact there are many advantages to publishing in the current publication system but there are many disadvantages as well. With the widespread of social media an...
Source: Bulletin du Cancer - May 22, 2018 Category: Cancer & Oncology Authors: Rached G, Hobeika C, Karam E, Kourié HR, Kattan J Tags: Bull Cancer Source Type: research

[The role and use of Patient Reported Outcomes in the management of cancer patients].
Abstract Therapeutic innovations in the field of oncology allow to manage cancer as a chronic illness with treatments being administered over prolonged periods of time. In this context, it is now acknowledged that it is important to complete the assessment of benefit based on purely clinical endpoints using outcome measurement evaluated by patients themselves. The Patient reported outcome (PRO) concept has then emerged and there is an increasing interest in using the PROs as an indicator of the benefit of new therapeutic strategies. In this paper, we aim to illustrate the potential use and value of using PROs in t...
Source: Bulletin du Cancer - May 15, 2018 Category: Cancer & Oncology Authors: Marino P, Bannier M, Moulin JF, Gravis G Tags: Bull Cancer Source Type: research

[IDEA study (International Duration Evaluation of Adjuvant Chemotherapy) for patients with stage III colon cancer: Possibility of reducing to 3  months treatment for 60% of the patients!]
[IDEA study (International Duration Evaluation of Adjuvant Chemotherapy) for patients with stage III colon cancer: Possibility of reducing to 3 months treatment for 60% of the patients!] Bull Cancer. 2018 May 15;: Authors: André T, Taieb J, Pour l’intergroupe PRODIGE (GERCOR, Fédération française de cancérologie digestive, et Unicancer) et pour la Fondation ARCAD (Aide et recherche encancérologie digestive) PMID: 29776587 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - May 15, 2018 Category: Cancer & Oncology Authors: André T, Taieb J, Pour l’intergroupe PRODIGE (GERCOR, Fédération française de cancérologie digestive, et Unicancer) et pour la Fondation ARCAD (Aide et recherche encancérologie digestive) Tags: Bull Cancer Source Type: research

[Cognitive decline in geriatric oncology: Trends, evaluation and treatment].
Abstract Cancer prevalence increases with aging. Prevalent or incident neurocognitive disorders are frequent in geriatric oncology. Cognitive decline associated with cancer increases the risk of under or over-cancer treatment and makes therapeutic decisions complex. In this context, we present tools to optimize cognitive impairment screening, identification of underlying mechanisms and specific treatments. Geriatric specialists intervention can help global care, social services utilization and patient's orientation when ambulatory cares become difficult. PMID: 29773225 [PubMed - as supplied by publisher] (Sou...
Source: Bulletin du Cancer - May 14, 2018 Category: Cancer & Oncology Authors: Antoine V, Courtial M, de Wazieres B, Di Castri A, Duvjnak S, Geronimi L, Labarias C, Le Guillou C, Martin-Allier A, Matelot D, Moitrelle C, Santoni F, Solinas G, Viala M Tags: Bull Cancer Source Type: research

[WHO classification of head and neck tumours 2017: Main novelties and update of diagnostic methods].
Abstract The publication of the new WHO classification of head and neck tumours in 2017 brought major modifications. Especially, a new chapter is dedicated to the oropharynx, focusing on the description of squamous cell carcinoma induced by the virus Human Papilloma Virus (HPV), and new entities of tumors are described in nasal cavities and sinuses. In this article are presented the novelties and main changes of this new classification, as well as the updates of the diagnostic methods (immunohistochemistry, cytogenetics or molecular biology). PMID: 29759330 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - May 11, 2018 Category: Cancer & Oncology Authors: Sarradin V, Siegfried A, Uro-Coste E, Delord JP Tags: Bull Cancer Source Type: research

[The French health care funding system for research and innovation in oncology].
CONCLUSION: Changes in the health research funding system have an incentive purpose. They have significantly modified the global healthcare landscape. Feedback on these changes will be necessary to assess the success of the reinforcement of the dynamics of research and innovation. PMID: 29747854 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - May 7, 2018 Category: Cancer & Oncology Authors: Wiernik H, Katz G, Coulonjou H, Salagnac A, Kletz F, Thariat J Tags: Bull Cancer Source Type: research

[Psychological impact of ostomy on the quality of life of colorectal cancer patients: Role of body image, self-esteem and anxiety].
This study explores, on the one hand, the psychological impact of colostomy on colorectal cancer patients' quality of life and on the other hand, it analyzes the correlational links between body image, self-esteem and anxiety during the stoma. Thirty-five patients with colorectal cancer participated in the study, divided into 2 subgroups: 23 were carriers of a definitive stoma and the 12 others with a temporary stoma. All completed the Functional Assessment Cancer Therapy (FACT-C), the Body Image Scale (BIS), the State Trait Anxiety Inventory (STAI-Y) and the Self Esteem Scale (ETES). Analysis revealed the quality of life ...
Source: Bulletin du Cancer - May 4, 2018 Category: Cancer & Oncology Authors: Beaubrun En Famille Diant L, Sordes F, Chaubard T Tags: Bull Cancer Source Type: research

Characteristics of adult patients treated for acute myeloid leukemia with inv 16 in Casablanca (Morocco).
PMID: 29735159 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - May 4, 2018 Category: Cancer & Oncology Authors: Houssou B, Lamchahab M, Massi R, Oukkache B, Quessar A Tags: Bull Cancer Source Type: research

[Adherence to the Clinical Practice Guidelines in the management of Soft Tissue Sarcomas in Lebanon: Lessons from French Sarcoma Group's experience].
PMID: 29729806 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - May 2, 2018 Category: Cancer & Oncology Authors: Assi T, El Rassy E, Kattan J Tags: Bull Cancer Source Type: research

[CDK4/6 inhibitors: biomarkers, mechanisms of resistance and interest of the study of the circulating tumor DNA].
ves A PMID: 29729807 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - May 2, 2018 Category: Cancer & Oncology Authors: Gonçalves A Tags: Bull Cancer Source Type: research

Urothelial carcinoma in children: A case series.
CONCLUSIONS: In this study, UBCs presenting at a young age were low-grade and have not recurred in follow-up. This confirms the results of other series reported in Literature. Therefore there might be the space to perform a follow-up dedicated to children. PMID: 29724585 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - April 30, 2018 Category: Cancer & Oncology Authors: Marinoni F, Destro F, Selvaggio GGO, Riccipetitoni G Tags: Bull Cancer Source Type: research

[Tunisian National Protocol for Adult Hodgkin's Lymphoma Treatment: Results of a therapeutic regimen adapted to the 2-cycle CT response, about 444 patients].
CONCLUSION: Compared to MDH2002 (second version of Tunisian prospective protocol), the MDH2008 reduced the primary failure rate, the rate of toxic deaths with escalated BEACOPP and the rate of relapse in Tunisian patients. PMID: 29709235 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - April 27, 2018 Category: Cancer & Oncology Authors: Ben Lakhal R, Hdiji S, Zriba S, Mokrani A, Laatiri MA, BenYoussef Y, Ezzaier F, Toumi N, Ladeb S, BenSalah H, Tebra S, Frikha H, Messai T, Daoued J, Bouaouina N, Maalej M, Frikha M, BenOthmen T, BenAhmed S, Khelif A, Msaddek F, Mezlini A, Elloumi M, Medde Tags: Bull Cancer Source Type: research

[ROS-1 rearranged bronchopulmonary adenocarcinoma revealed by a pulmonary miliary].
PMID: 29706357 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - April 26, 2018 Category: Cancer & Oncology Authors: Brindel A, Huet D, Vaillant P, Vignaud JM, Tiotiu A Tags: Bull Cancer Source Type: research

[Novel strategy in oncoimmunology].
Abstract Recent advances in immuno-oncology with the development of anti-PD1/PD-L1 antibodies are revolutionizing oncological management. Immuno-oncology I currently developing in most histological types of cancer. However, the rate of success of anti-PD1/PD-L1 antibodies in monotherapy is limited by a limited to a subpopulation of patients accounting for about 25-30 % of patients in most indications. The development of new strategies is based on this observation with the aim to predict response or enhancing response rate. Thus, we note the development of different strategies aimed at better selecting patient...
Source: Bulletin du Cancer - April 25, 2018 Category: Cancer & Oncology Authors: Ghiringhelli F Tags: Bull Cancer Source Type: research

[Clinical practice for morbidly obese endometrial cancer patients: A french multicentric study].
DISCUSSION: Although good prognosis, the endometrial cancer of morbidly obese women seem to be under treat. These patients do not seem benefited an optimal pre-operative assessment. The surgery is mainly realized by laparotomy with a not complete surgical stadification for one more than a third of the patients. PMID: 29681402 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - April 19, 2018 Category: Cancer & Oncology Authors: Loaec C, Vaucel E, Darnis E, Lopes P, Selmes G, Jaffre I, Classe JM Tags: Bull Cancer Source Type: research

Management of venous thromboembolism in cancer patients according to guidelines after educative measures.
Abstract Guidelines for venous thromboembolism treatment with curative anticoagulation in cancer patients are poorly respected. Yet, venous thromboembolism is the second leading cause of death in cancer patients, after cancer progression. The aim of this study was to re-evaluate the application of these guidelines after the implementation of educational measures for patients and caregivers, and also to assess the acceptability and tolerance of treatment by patients. On the one hand, a prospective observational study conducted in cancer patients with VTE allowed to assess the rate of compliance to guidelines. These...
Source: Bulletin du Cancer - April 18, 2018 Category: Cancer & Oncology Authors: Pillet A, Minne F, Belhadj Chaidi R, Chapelle G, Ferru A Tags: Bull Cancer Source Type: research

Cancer Immunotherapy 2017 (Paris, France). Progress and challenges.
PMID: 29656785 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - April 12, 2018 Category: Cancer & Oncology Authors: Chouaieb E, Terry S, Corgnac S, Engelsen AST Tags: Bull Cancer Source Type: research

[Radiation therapy in patients with inflammatory bowel disease. A review].
Abstract Inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, are multifactorial diseases characterized by a chronic intestinal inflammation. Abdominal and pelvic irradiation can result in acute or chronic digestive toxicity. A few old studies on small population samples have suggested an increase of gastro-intestinal toxicities in patients with IBD in case of irradiation. Nevertheless, the physiopathology is unknown. More recent studies, including new irradiation techniques, have shown less toxicity events in these patients with IBD. There are no recommendations for irradiation in p...
Source: Bulletin du Cancer - April 10, 2018 Category: Cancer & Oncology Authors: Jmour O, Pellat A, Colson-Durand L, To NH, Latorzeff I, Sargos P, Sobhani I, Belkacemi Y Tags: Bull Cancer Source Type: research

[Neoadjuvant chemotherapy with concurrent chemoradiotherapy in the treatment of nasopharyngeal cancer: Southern Tunisian experience].
CONCLUSION: Induction chemotherapy by docetaxel, cisplatin and 5-fluoro-uracil is a safe and effective option in the treatment of nasopharyngeal carcinoma. A better definition of high risk of relapse group would optimize the indications of this chemotherapy in the therapeutic arsenal. PMID: 29650393 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - April 9, 2018 Category: Cancer & Oncology Authors: Mnejja W, Toumi N, Fourati N, Bouzguenda R, Ghorbel A, Frikha M, Siala W, Daoud J Tags: Bull Cancer Source Type: research

[Desmoplastic small round cell tumor in children, adolescents and young adults].
ach D Abstract Desmoplastic small round cell tumor (DSRCT) is a rare sarcoma that typically affects pediatric and young adult patients with a median age in the general and in the pediatric population of 24.6 years (range 4-58 years) and 15.0 years (range 0-21 years) respectively, with a strong male predominance. This tumor is characterized by a specific t(11;22)(p13;q12) that results in fusion of EWS and WT1 genes which can be demonstrated by RT-PCR or by FISH. DSRCT most frequently presents as an intra-abdominal primary mass associated with peritoneal seeding and a highly aggressive pattern of spread. Generally, ...
Source: Bulletin du Cancer - March 22, 2018 Category: Cancer & Oncology Authors: de Marcellus C, Sarnacki S, Pierron G, Ranchère-Vince D, Scalabre A, Bolle S, Minard-Colin V, Corradini N, Fayard C, Orbach D Tags: Bull Cancer Source Type: research

Blocking Tim-3 or/and PD-1 reverses dysfunction of tumor-infiltrating lymphocytes in HBV-related hepatocellular carcinoma.
CONCLUSION: Expression of Tim-3 and/or PD-1 on TILs impairs their function and correlates negatively with disease-free survival in HBV-HCC. Direct blockade of Tim-3 and PD-1 restores anti-tumor effects of TILs, which suggests a potential target for novel immunotherapy in HBV-HCC. PMID: 29576222 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - March 22, 2018 Category: Cancer & Oncology Authors: Liu F, Zeng G, Zhou S, He X, Sun N, Zhu X, Hu A Tags: Bull Cancer Source Type: research

[Development of a standardized guide for optimizing drug adherence information to be dispensed during a pharmaceutical counseling with a multiple myeloma patient: Initial validation].
This study carried out the initial validation of documents to standardize the pharmaceutical counseling for patients treated for myeloma so that it can be reproduced from one patient to another regardless of the pharmacist, by standardizing the information issued. This study needs to be completed by a final validation in myeloma patients, free from oral anticancer therapies. PMID: 29573809 [PubMed - as supplied by publisher] (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - March 21, 2018 Category: Cancer & Oncology Authors: Favier-Archinard C, Leguelinel-Blache G, Dubois F, Le Gall T, Bourquard P, Passemard N, Tora S, Rey A, Rossi M, Chevallier T, Cousin C, Favier M Tags: Bull Cancer Source Type: research

[Benign aggressive vascular anomalies in children].
-Labrèze C Abstract Superficial vascular anomalies constitute a large group of malformative and tumoral conditions developed from all types of vessels. Vascular tumors are the result of cellular hyperplasia, whereas vascular malformations (VMs) are constituted of dysplastic vessels. The classification from International Society for the Study of Vascular Anomalies (ISSVA) is based on this pathogenic difference. The most common vascular tumor is infantile hemangioma, which treatment, when necessary, is propranolol. Congenital hemangiomas and tumors that might be complicated with Kasabach-Merritt phenomenon, i...
Source: Bulletin du Cancer - March 20, 2018 Category: Cancer & Oncology Authors: Boccara O, Maruani A, Léauté-Labrèze C Tags: Bull Cancer Source Type: research

[Neuroendocrine tumors of the breast: Myth or reality? A systematic review].
Abstract Primary neuroendocrine breast carcinomas are rare and little-known tumors. Only a limited number of studies on neuroendocrine breast carcinomas have been reported in the literature, and the vast majority of them are small retrospective series or case reports. According to the World Health Organization (WHO), they account for only 2 % to 5 % of breast cancers. Their diagnosis relies on the presence of a neuroendocrine architecture and the expression of neuroendocrine markers (chromogranin A and/or synaptophysin). The revised 2012 WHO classification subdivides them into three categories: (i) well-...
Source: Bulletin du Cancer - March 19, 2018 Category: Cancer & Oncology Authors: Cheymol C, Abramovici O, Do Cao C, Dumont A, Robin YM, El Hajbi F, Dansin E, Bonneterre J, Lauridant G Tags: Bull Cancer Source Type: research